未分化甲状腺癌的分子病理学:144例回顾性研究
该回顾性研究从法国10个中心收集144例未分化甲状腺癌(ATC)病例,检测ALK重排及50基因 panel 和TERT启动子突变。结果显示ALK重排罕见(可判读90例中1例阳性),突变谱高度异质,TP53改变最常见(54.4%),TERT启动子突变占54.0%,部分基因编码潜在可靶向目标。
要点
- ATC中ALK重排罕见,可判读90例中仅1例(1.1%)阳性且为临界阈值。
- TP53改变最常见(54.4%),RAS基因突变占43%,BRAF突变占13.8%。
- TERT启动子突变见于53例(54.0%),包括43例C228T和10例C250T。
核心结论
- 本研究证实ATC中ALK重排罕见,且ATC突变谱高度异质,许多基因参与滤泡上皮细胞去分化过程。
- 这可能解释迄今测试的靶向治疗选择效果有限。
研究设计与样本
- 回顾性研究,从法国难治性甲状腺肿瘤管理国家网络的10个中心收集144例ATC病例。
- 对组织芯片进行ALK重排的荧光原位杂交分析,并采用二代测序筛查50个基因 panel 及Sanger测序检测TERT启动子突变。
主要发现
- 荧光原位杂交可判读90例(62.5%),其中1例(1.1%)ALK重排阳性,阳性细胞比例为15%的临界阈值。
- 二代测序可判读94例(65.3%),Sanger测序(TERT)可判读98例(68.1%),共鉴定210个突变(内含子和外显子)。
- TP53改变最常见(54.4%),43%存在(H-K-N)RAS基因突变,13.8%存在BRAF基因突变(主要为p.V600E),17%存在PI3K-AKT通路突变,6.4%同时存在RAS和PI3K通路突变,4.3%同时存在TP53和PTEN突变。
- 近10%的病例无RAS、PI3K-AKT通路或TP53突变,而存在ALK、ATM、APC、CDKN2A、ERBB2、RET或SMAD4突变,包括尚未在甲状腺肿瘤中描述的突变。
- 编码潜在可靶向目标的基因突变包括:ATM基因突变4例(4.3%),ERBB2突变1例(1.1%),MET突变1例(1.1%),ALK突变1例(1.1%)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anaplastic thyroid carcinoma (ATC) is a rare tumor, with poorly defined oncogenic molecular mechanisms and limited therapeutic options contributing to its poor prognosis. The aims of this retrospective study were to determine the frequency of anaplastic lymphoma kinase (ALK) translocations and to identify the mutational profile of ATC including TERT promoter mutations. METHODS AND MATERIALS: One hundred and forty-four ATC cases were collected from 10 centers that are a part of the national French network for management of refractory thyroid tumors. Fluorescence in situ hybridization analysis for ALK rearrangement was performed on tissue microarrays. A panel of 50 genes using next-generation sequencing and TERT promoter mutations using Sanger sequencing were also screened. RESULTS: Fluorescence in situ hybridization was interpretable for 90 (62.5%) cases. One (1.1%) case was positive for an ALK rearrangement with a borderline threshold (15% positive cells). Next-generation sequencing results were interpretable for 94 (65.3%) cases, and Sanger sequencing (TERT) for 98 (68.1%) cases. A total of 210 mutations (intronic and exonic) were identified. TP53 alterations were the most frequent (54.4%). Forty-three percent harbored a mutation in the (H-K-N)RAS genes, 13.8% a mutation in the BRAF gene (essentially p.V600E), 17% a PI3K-AKT pathway mutation, 6.4% both RAS and PI3K pathway mutations, and 4.3% both TP53 and PTEN mutations. Nearly 10% of the cases showed no mutations of the RAS, PI3K-AKT pathways, or TP53, with mutations of ALK, ATM, APC, CDKN2A, ERBB2, RET, or SMAD4, including mutations not yet described in thyroid tumors. Genes encoding potentially druggable targets included: mutations in the ATM gene in four (4.3%) cases, in ERBB2 in one (1.1%) case, in MET in one (1.1%) case, and in ALK in one (1.1%) case. A TERT promoter alteration was found in 53 (54.0%) cases, including 43 C228T and 10 C250T mutations. Three out of our cases did not harbor mutations in the panel of genes with therapeutic interest. CONCLUSION: This study confirms that ALK rearrangements in ATC are rare and that the mutational landscape of ATC is heterogeneous, with many genes implicated in the follicular epithelial cell dedifferentiation process. This may explain the limited effectiveness of targeted therapeutic options tested so far.
引用
- Bonhomme B, Godbert Y, Perot G, et al. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases. Thyroid. 2017. PMID: 28351340. doi:10.1089/thy.2016.0254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。